肿瘤与非肿瘤相关主动脉-食管及主动脉-支气管瘘的管理
该回顾性研究纳入2011至2019年连续16例主动脉-食管瘘(AEF,n=10)和主动脉-支气管瘘(ABF,n=6)患者,其中肿瘤相关(TR)8例、非肿瘤相关(NTR)8例。胸主动脉腔内修复(TEVAR)应用于13例,技术成功率100%。NTR组院内、6个月、1年死亡率分别为0%、25%、25%,TR组分别为63%、88%、100%;存活5例均为NTR ABF。结论认为TEVAR对NTR ABF可靠,对TR瘘和NTR AEF应更选择性应用,死亡率仍很高。
要点
- TEVAR可用于NTR主动脉-支气管瘘,技术成功率高。
- TR瘘与NTR主动脉-食管瘘应用TEVAR需更谨慎选择。
- TR组1年死亡率达100%,NTR组为25%。
核心结论
- TEVAR是治疗非肿瘤相关主动脉-支气管瘘的可靠选择。
- 肿瘤相关瘘和非肿瘤相关主动脉-食管瘘应更选择性地应用TEVAR,相关死亡率仍很高。
研究设计与样本
- 回顾性系列研究,纳入2011至2019年连续16例患者,肿瘤相关8例、非肿瘤相关8例,主动脉-支气管瘘6例、主动脉-食管瘘10例。
主要发现
- 中位年龄62岁(范围46-81),男性11例。
- 最常见诱因为食管癌或胃贲门癌(6例),其次为胸主动脉开放修复(5例)。
- 腔内负压治疗(Endo-SPONGE®)相关主动脉-食管瘘3例。
- TEVAR应用于13例(主动脉-支气管瘘4例、主动脉-食管瘘9例),原发技术成功率100%。
- 1例(8%)术后并发大脑中动脉综合征和左侧偏瘫。
关键数值与推荐
- 非肿瘤相关组院内、6个月、1年死亡率分别为0%(0例)、25%(2例)、25%(2例)。
- 肿瘤相关组院内、6个月、1年死亡率分别为63%(5例)、88%(7例)、100%(8例)。
- 平均随访13个月后5例(31%)存活,1例在11个月后失访。
- 存活5例均为非肿瘤相关主动脉-支气管瘘。
- 死亡最常见原因为基础癌症进展和血流动力学休克。
临床怎么用
- 对非肿瘤相关主动脉-支气管瘘可优先考虑TEVAR治疗。
- 对肿瘤相关瘘和非肿瘤相关主动脉-食管瘘应个体化评估,选择性应用TEVAR。
- 需关注术后神经系统并发症及基础疾病进展导致的死亡风险。
局限性
- 回顾性设计,样本量小(16例),结果需谨慎解读。
- 单中心研究,可能存在选择偏倚。
- 随访时间有限,1例失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aims to review and compare the clinical presentation, management, and outcome in patients with tumor-related (TR) and nontumor-related (NTR) aorto-esophageal fistula (AEF) and aorto-bronchial fistula (ABF) with particular focus on the thoracic endovascular aortic repair. METHODS: We retrospectively reviewed a series of 16 consecutive patients with TR (n = 8) and NTR (n = 8), ABF (n = 6), and AEF (n = 10) admitted to our hospital from 2011 to 2019. RESULTS: The median age was 62 years (range 46-81), with 11 men. The most common predisposing factor was esophageal or gastric cardia cancer (n = 6), followed by open repair of the thoracic aorta (n = 5). Endoluminal vacuum therapy (Endo-SPONGE®) accounted for 3 cases of AEFs. Thoracic endovascular aortic repair (TEVAR) was applied in 13 patients (4 with ABFs and 9 with AEFs). The primary technical success of the TEVARs was 100%. One patient (8%) was complicated with postoperative middle cerebral artery syndrome and left-sided hemiparesis. The respective in-hospital, 6-month, and 1-year mortality rates were 0% (n = 0), 25% (n = 2), and 25% (n = 2) for the NTR group and 63% (n = 5), 88% (n = 7), and 100% (n = 8) for the TR group. After a mean period of 13 months, 5 (31%) patients were still alive, and one patient lost to follow-up after 11 months. The survivors (n = 5) had all nontumor-related ABF. Progression of underlying cancer and hemodynamic shock were the most common causes of death. CONCLUSIONS: TEVAR represents a reliable option in the treatment of NTR ABFs. In the cases of TR fistulas and NTR AEFs, TEVAR should be applied more selectively. The associated mortality remains very high.
引用
- Omran S, Ardalani L, Beyer K, et al. Management of Tumor- and Nontumor-related Aorto-esophageal and Aorto-bronchial Fistulas. Ann Vasc Surg. 2020. PMID: 33227472. doi:10.1016/j.avsg.2020.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。